Companies · Biotechnology

Genialis, Inc.

BOSTON · Biotechnology

Diligence memoA one-page analyst read on Genialis, Inc. — recommendation, valuation, rhythm, risks.
$12.1M
Total raised · real
2
Rounds
0.1×
Latest step-up
Top 42%
Sector rank · raised
Series A
Latest stage · inferred · Wed Dec 17 2025 00:00:00 GMT+0000 (Coordinated Universal Time)

Genialis, Inc. looks under-valued against its niche peers and is active on financing cadence.

Synthesized from the figures below est. — every claim rests on a number shown on this page. Valuation uses the biotech sector profile.

Analyst read est. — computed against this company's niche peers in the same era. Inputs shown; not a quoted figure.

Under-valued
  • Modeled value is 0.12× the median modeled value of Series A Biotechnology companies in 2025–2027 (156 peers) — value vs value, same stage and era.
Active
  • Last raise 6 mo ago; this sector typically re-raises about every 14 months.
  • Raising on or ahead of the sector's normal rhythm.
Leadership

No named principal in this company's public records yet — see all operators below.

Explore how these operators interlock with other companies in the operator network.

Where it sits in Biotechnology

Genialis, Inc. is one of 4291 Biotechnology companies tracked from BOSTON. By capital raised it ranks mid-pack (ahead of 59% of sector peers), and in the long tail by modeled valuation est..

Ranking is computed against this company's own sector cohort — reported capital is fact; valuation tiers are modeled.

As reported in public records reported — not modeled.

US
Jurisdiction
Rule 506(b)
Reg D exemption
2
Investors (latest)
2025-12-17
First sale
Amount raised vs valuation, by round

Solid bars are reported offering amounts reported; hatched bars are the modeled post-money valuation est. — both on one shared scale so you can read raise-vs-worth at each round directly. Use the toggles to overlay data labels and the niche-peer / market average value lines.

Amount raised · realModeled valuation · estCumulative funded · real
$0$50M$100M$150M$200MSeries A · 2023-01-19 Raised $11M (real) Modeled valuation $121M (est)$11M$121MSeries A2023Series A · 2025-12-17 Raised $700K (real) Modeled valuation $1.8M (est)$700K$1.8MSeries A2025+$700KCumulative $12M

The line shows cumulative reported funding over the period; + labels show new capital added between points when there is room. Toggle on-bar figures, plus the niche-peer and market averages, to read this company against its cohort. Benchmarks are modeled medians.

Financing ladder & sequence gaps
Series A$11.4M · 2023
Series A extension$700K · 2025

Stages are modeled from round size (public records carry no series label). No record for: Pre-Seed, Seed — the company may have raised it under a different exemption, merged it into an adjacent record, or skipped it. Sequence completeness: 33%.

Modeled valuation trajectory
$1.8M
Base estimate est.
$764K
Conservative case
$2.8M
Upside case
$3.2M
Modeled post-money

Round size and date are reported; the stage label is inferred from round size (latest is Series Aa $4.0M–$15M round). Valuation is modeled from stage benchmarks scaled by the biotech sector profile. Directional, not a quoted figure.

Series A · modeled $120.5M · 2023-01-192023Series A · modeled $1.8M · 2025-12-172025
Model inputs · modeled:benchmark-stage-stepup-v1
22%
Dilution assumption
Implied ownership sold in the financing.
44%
Survival probability
24% low · 60% high
1.62×/yr
Annual markup
2.04×/yr upside case
0.5 yr
Elapsed time used
0.5 yr actual, capped for stale marks
biotech
Sector profile
Adjusts growth and survival by industry.
Financing rhythm
35 mo
Avg between rounds
$4.2M/yr
Capital velocity
3.4 yr
On record since
2023
First round
2
Rounds on file
How it compares to the market

Benchmarked against 4291 companies in Biotechnology. Each bar is a median (the middle company, not an average — outliers don't skew it). Two yardsticks: real money raised (reported on Form D) and modeled value (our estimate est.). These are whole-sector medians across all stages, except the per-stage row.

Total raised — vs sector median (real $, all stages) 1.7× above median
This company$12.1M
Sector median$7.2M
Latest round — vs other Series A rounds in sector (real $, this stage) 0.1× of median
This company$700K
Sector median$5.4M
Modeled value — vs sector median (estimate, all stages) 0.0× of median
This company$1.8M
Sector median$64.2M

Raised more than 59% of sector peers (real $). Modeled value above 5% of peers (estimate).

Niche peers — same stage & era

A tighter cohort than the sector chart above — only companies at the same stage (Series A) that last raised in the same ~3-year era, ranked by modeled value est. (not money raised). This is the exact set the analyst read compares against, so a like-for-like cohort is what makes "over/under-valued" meaningful. This company ranks #140 of 156.

This companyCohort peer
$1.0M$10.0M$100.0M$10.0M$100.0MCapital raised (log)Acasti Pharma Inc. · Series A Raised $23.0M · modeled $58.5M (est)Edesa Biotech, Inc. · Series A Raised $36.9M · modeled $58.4M (est)4DMedical Ltd · Series A Raised $15.0M · modeled $50.6M (est)Arialys Therapeutics, Inc. · Series A Raised $29.1M · modeled $49.1M (est)Nuclein, LLC · Series A Raised $34.5M · modeled $48.3M (est)Phantom Neuro Inc. · Series A Raised $15.4M · modeled $45.7M (est)Circulate Health, Inc. · Series A Raised $13.0M · modeled $43.2M (est)Biovantix Biotechnology, Inc · Series A Raised $15.0M · modeled $42.1M (est)Bariendo Inc. · Series A Raised $11.1M · modeled $40.9M (est)ENDRA Life Sciences Inc. · Series A Raised $26.8M · modeled $40.8M (est)Medici Therapeutics, Inc. · Series A Raised $14.8M · modeled $39.7M (est)Onconetix, Inc. · Series A Raised $22.0M · modeled $37.7M (est)Genialis, Inc. (this company) Raised $12.1M · modeled $1.8M (est)Genialis, Inc.
CompanyStageRaised · realValue · estvs peer med.
Acasti Pharma Inc.Series A$23.0M$58.5M3.76×
Edesa Biotech, Inc.Series A$36.9M$58.4M3.75×
4DMedical LtdSeries A$15.0M$50.6M3.25×
Arialys Therapeutics, Inc.Series A$29.1M$49.1M3.15×
Nuclein, LLCSeries A$34.5M$48.3M3.10×
Phantom Neuro Inc.Series A$15.4M$45.7M2.93×
Circulate Health, Inc.Series A$13.0M$43.2M2.77×
Biovantix Biotechnology, IncSeries A$15.0M$42.1M2.70×
Bariendo Inc.Series A$11.1M$40.9M2.62×
ENDRA Life Sciences Inc.Series A$26.8M$40.8M2.62×
Medici Therapeutics, Inc.Series A$14.8M$39.7M2.55×
Onconetix, Inc.Series A$22.0M$37.7M2.42×
Genialis, Inc. this companySeries A$12.1M$1.8M0.12×
Full financing history

Stage is inferred from round size est., not reported on the filing — a round's dollar size maps to a bucket: Pre-Seed <$1.0M · Seed $1.0M–$4.0M · Series A $4.0M–$15M · Series B $15M–$40M · Series C $40M–$100M · Series D+ $100M–$400M · Growth/Late >$400M.

StageAmount · realAnnouncedPost-money · estValue · estConf.
Series A$11.4M2023-01-19$51.9M$120.5M90%
Series A$700K2025-12-17$3.2M$1.8M90%
What happened at each round

Step-up, pace versus the sector's normal cadence, and revenue/exemption moves — read straight from the reported round facts reported.

  1. Series A$11.4M2023-01-19
    • First recorded raise — entered as Series A.
    • 10 investors on this round.
  2. Series A$700K2025-12-17
    • Raised again after 35 mo — slower than the ~14 mo sector norm.
    • Round 16.3× smaller than the prior — bridge or down round.
    • 2 investors on this round.
Intelligence
2028 ~Q4
Modeled next raise · ~35mo cadence
$700K
Modeled next size est.range $700K$1.1M
0.1×
Last step-up
$4.2M/yr
Capital velocity

Predictive signals are modeled est. from this company's own cadence and step-up, plus sector benchmarks — directional, not advice. Peer set and a CSV export live in your analyst workspace.

Key people & operators

Officers, directors and promoters named in this company's public recordsreported — the people who run it (not its investors). "Also runs" counts come from name-matching across all records, so verify before acting.

PersonRoleAlso runsTied since
Krista McKerracher1 other2025-12
Cedric Hermann Odje2025-12
Drew Krisper Volpe2023-01
Elia Hermann Stupka2025-12
Elia Krisper Stupka2023-01
Hamzeh Krisper Abdul-Hadi2023-01
Ita Krisper Lu2023-01
Ita Lu2025-12
Luka Ausec2025-12
Luka Krisper Ausec2023-01
Miha Stajdohar2023-01
Nadine Krisper Geiser2023-01
Rafael Rosengarten2023-01
Tjasa Krisper Kutin2023-01
Registry & provenance

Genialis, Inc. is an official record sourced from the U.S. Securities and Exchange Commission (SEC). U.S. data is aggregated from SEC Form D filings.

United States
Country of record
US
Jurisdiction
1948756
SEC CIK
Similar companies

Nearest neighbours across the whole database — matched on sector, stage and capital scale, and on shared operators (officers or directors named at both companies in public filings). A discovery shortlist, not a valuation cohort — verify before acting, the same way modeled figures are directional.

CompanySectorStageRaised · realValue · estWhy similar
Navrogen Inc.BiotechnologySeries A$12.8M$2.9Msame sector · same stage
Memgen, Inc.BiotechnologySeries A$13.0M$4.1Msame sector · same stage
Orion Biotechnology Canada Ltd.BiotechnologySeries A$11.2M$3.9Msame sector · same stage
Biopoly, LlcBiotechnologySeries A$13.2M$4.3Msame sector · same stage
Elastrin Therapeutics, Inc.BiotechnologySeries A$13.3M$2.4Msame sector · same stage
Pirouette Medical Inc.BiotechnologySeries A$14.0M$2.5Msame sector · same stage
Suono Bio, Inc.BiotechnologySeries A$14.0M$4.0Msame sector · same stage
Mel-Mont Medical, Inc.BiotechnologySeries A$10.2M$653Ksame sector · same stage
Semantically similar

Matched by meaning, not labels — a local language model reads each company's name, sector and description and ranks the closest in that learned space. This catches look-alikes that cross sector boundaries; the structured list above explains its matches, this one trusts the text. Directional, like every modeled signal here.

CompanySectorStageValue · estMatch
Gennao Bio, Inc.BiotechnologySeries B$211.6M89%
Genix BioMed, Inc.BiotechnologySeries A$361.5M89%
Genocea Biosciences, Inc.BiotechnologySeries C$3.0B89%
Genapsys, Inc.BiotechnologySeries B$870.9M89%
Genprex, Inc.BiotechnologySeries A$52.7M87%
Genten Therapeutics, Inc.BiotechnologySeries A$433.8M86%
Medivis, Inc.BiotechnologySeries B$349.5M86%
Generation Bio Co.BiotechnologySeries D+$4.6B85%
Frequently asked
How much funding has Genialis, Inc. raised?
Genialis, Inc. has raised approximately $12.1M in disclosed capital across 2 recorded financing rounds, aggregated from public filings.
What is Genialis, Inc.'s estimated valuation?
Provath's modeled valuation for Genialis, Inc. is approximately $1.8M (modeled range $764K–$2.8M). This is an algorithmic estimate derived from round sizes and same-niche peers — not a quoted or reported figure.
What funding stage is Genialis, Inc. at?
Genialis, Inc.'s latest modeled financing stage is Series A. Its most recent recorded round closed around Wed Dec 17.
What does Genialis, Inc. do and where is it based?
Genialis, Inc. operates in the Biotechnology sector, based in BOSTON.
Explore related

See where Genialis, Inc. sits in the wider market — its sector, location and stage cohorts, each with their own leaderboards and capital-flow timelines.

Is this your company?

If you work at Genialis, Inc., claim this profile or suggest a correction. We aggregate from public filings, so help us keep your description, website and links accurate.

Is this your company? Update your profile or add contact details — and choose exactly who can reach you. Reviewed before anything is published.